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Abstract
Introduction
Previous studies have shown increased expression of stromal markers in synovial tissue
(ST) of patients with established rheumatoid arthritis (RA). Here, ST expression of stromal
markers in early arthritis in relationship to diagnosis and prognostic outcome was studied.
Methods
ST from 56 patients included in two different early arthritis cohorts and 7 non-inflammatory
controls was analysed using immunofluorescence to detect stromal markers CD55, CD248,
fibroblast activation protein (FAP) and podoplanin. Diagnostic classification (gout, psoriatic
arthritis, unclassified arthritis (UA), parvovirus associated arthritis, reactive arthritis and RA),
disease outcome (resolving vs persistent) and clinical variables were determined at baseline
and after follow-up, and related to the expression of stromal markers.
Results
We observed expression of all stromal markers in ST of early arthritis patients, independent
of diagnosis or prognostic outcome. Synovial expression of FAP was significantly higher in
patients developing early RA compared to other diagnostic groups and non-inflammatory
controls. In RA FAP protein was expressed in both lining and sublining layers. Podoplanin
expression was higher in all early inflammatory arthritis patients than controls, but did not
differentiate diagnostic outcomes. Stromal marker expression was not associated with
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Conclusions
Stromal cell markers CD55, CD248, FAP and podoplanin are expressed in ST in the earliest
stage of arthritis. Baseline expression of FAP is higher in early synovitis patients who fulfil
classification criteria for RA over time. These results suggest that significant fibroblast acti-
vation occurs in RA in the early window of disease.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting synovial tissue (ST) in
multiple joints leading to joint destruction, deformity and disability [1]. Classifying patients in
an early stage of the disease is important, as early appropriate treatment can reduce or even
prevent joint destruction [2]. Paradoxically, it is in the first three months of symptoms, when
optimal treatment most significantly improves outcomes, that patients with early symptoms
are most difficult to diagnose and many therefore remain unclassified [3–5], resulting in a
delay in optimal treatment. There is therefore a need for new diagnostic and prognostic mark-
ers. Evidence is starting to emerge that synovial tissue may be a valuable source of potential
biomarkers in the earliest stages of disease when diagnosis is unclear [6].
Stromal cells play an important role in organising the structure of ST by producing extracel-
lular matrix components, recruiting infiltrating immune cells and secreting inflammatory
mediators. Furthermore, considerable evidence exists supporting a role for these cells in driv-
ing the persistence of inflammation and joint damage in RA [7–9]. The addition of novel stro-
mal markers to existing markers such as VCAM-1, CD55 and cadherin-11 has resulted in an
increasing ability to delineate subpopulations of fibroblast-like cells in the synovium that may
possess differing functional properties and act as both biomarkers of outcome and novel thera-
peutic targets [10].
Previous work has suggested that the synovial compartment of patients with short duration
RA is rich in stromal growth factors [11, 12]. In patients with early RA, concentrations of basic
fibroblast growth factor and epidermal growth factor in synovial fluid are significantly higher
compared to both patients with early arthritis developing non-RA diseases and patients with
longer duration established RA (11). We therefore hypothesised that subpopulations within
the stromal compartment might become activated and expanded during the inflammatory
processes occurring in early disease, defining a profile that may be specific for RA. We chose
to examine an established intimal lining layer stromal marker (CD55) [13, 14], and more
recently discovered markers described both in RA and cancer, where the role of tumour-asso-
ciated fibroblasts has become prominent. These include CD248 [15, 16], a synovial sublining
glycoprotein marker expressed in perivascular and cancer stromal cells and in the RA syno-
vium; fibroblast activation protein (FAP) [17–19], a cell surface protein that is highly expressed
in established RA synovium with ectoenzyme activity and an important role in epithelial can-
cers; and podoplanin (gp38) [20–22], an intimal lining layer glycoprotein marker with roles in
lymph node stromal networks and epithelial to mesenchymal transition. Using the combined
resources of two collaborating cohorts with aligned data and tissue sample collection proto-
cols, we tested the hypotheses that tissue stromal markers measured during the first three
months of symptom duration would (a) differentiate diagnostic groups, and (b) distinguish
between prognostic outcomes of persistence and resolution. We also examined whether
Stromal cell markers in early arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0182751 August 9, 2017 2 / 17
Initiative project BTCure (grant agreement number
115142-1 for DMG). The research leading to these
results received funding from the European
Community’s Collaborative project FP7-HEALTH-
F2-2012-305549 (EuroTEAM) for DMG. Funding
was also provided by Arthritis Research UK
(Fellowship 18547 and the RACE Rheumatoid
Arthritis Pathogenesis Centre of Excellence grant
20298 for AF) and the Dutch Arthritis Foundation
(NR 07-010404) for DMG. The funders had no role
in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: Prof. Tak is currently also
employee at GlaxoSmithKline, Stevenage, UK, and
Dr. Gerlag is currently also employee at
GlaxoSmithKline, Cambridge, UK. GSK was not
involved in this study. The authors have declared
that no competing interests exist. This does not
alter our adherence to PLOS ONE policies on
sharing data and materials.
expression of stromal markers correlated with clinical and ultrasonographic measures of dis-
ease activity.
Methods
Cohorts and synovial tissue
Synovial tissues and clinical outcome data of patients included in two early arthritis cohorts in
Amsterdam (Synoviomics) and Birmingham (BEACON) were used in this study [23, 24].
Overlap of procedures for clinical data collection in the cohorts allowed comparison of all key
data variables. During establishment of ultrasound guided biopsy techniques in Birmingham
in 2007, standard operating procedures for tissue collection and processing were harmonised
with the Synoviomics project, leading to a common protocol for tissue recovery, processing
and storage. All patients were naïve to treatment with disease-modifying antirheumatic drugs
(DMARDs) and corticosteroids at inclusion.
Patients with clinical synovitis present in at least one synovial joint (of 66 joints examined)
were recruited to the BEACON cohort if symptom duration, defined as any symptom attrib-
uted by the assessing rheumatologist to inflammatory joint disease (pain, stiffness and/or
swelling) was no greater than 3 months [25, 26]. Consenting patients underwent ultrasound
guided synovial biopsy of an inflamed joint at baseline. Ultrasound guidance was used to in-
troduce a single portal through which tissue was sampled using 2.0mm cutting edged flexible
forceps (knee and ankle) or a 16G core biopsy needle (metacarpophalangeal joint) [6, 24].
Diagnostic and prognostic outcomes were assigned after 18-months of follow-up, with visits at
1, 2, 3, 6, 12 and 18 months. In Birmingham patients the joint to be biopsied was scanned
immediately prior to the procedure using a Siemens Acuson Antares scanner (Siemens PLC,
Bracknell, UK) and multifrequency (5-13MHz) linear array transducers. Findings of synovitis
and power Doppler (PD) positivity were defined using current consensus OMERACT defini-
tions [27]. Greyscale synovial hypertrophy and Power Doppler ultrasound variables were
graded on 0–3 semi-quantitative scales as previously reported [28].
In the Synoviomics cohort [23], patients presenting with arthritis of at least one knee, ankle
or wrist joint with duration of less than 1 year were included [29]. Arthritis duration was
defined as the time from the first clinical signs of arthritis, irrespective of which joint was ini-
tially affected, determined by an experienced rheumatologist; data on symptom duration were
also recorded, enabling comparison of patients between cohorts. At inclusion, synovial tissue
was collected during a mini-arthroscopy procedure as previously described [30]. Diagnostic
and prognostic outcomes were assigned after 2 years of follow up with minimum study visits
at 6 months, year 1 and year 2.
VERA was defined as any patient meeting RA criteria either at baseline or cumulatively
during subsequent study visits. In both cohorts, patients were classified as having RA accord-
ing to the 2010 ACR/EULAR classification criteria for RA [25, 26], psoriatic arthritis (PsA)
according to the CASPAR criteria for PsA [31], parvovirus arthritis based on clinical diagnosis
plus serological testing, and other diagnoses by characteristic clinical features, including the
presence of a pre-existing infectious episode (reactive arthritis) and uric acid crystals in syno-
vial fluid (gout). Patients were classified as having unclassified arthritis (UA) if they did not
meet any classification criteria. Patients were classified as having self-limiting disease if they
had no clinical evidence of synovial swelling and had not taken DMARDs or received gluco-
corticoid treatment in any form in the preceding 3 months.
We included ST of seven “non-inflammatory” control individuals with joint pain and nor-
mal MRI imaging who underwent exploratory arthroscopy during which no evidence of syno-
vial pathology was found macroscopically or on subsequent histological analysis.
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All studies were approved by local medical ethical committees and patients gave written,
informed consent to participate.
Tissue staining, immunofluorescence and confocal microscopy
Synovial tissue samples were snap-frozen in Tissue-Tek OCT medium (Miles, Elkhart, IN)
immediately after collection. In order to account for heterogeneity, six to eight biopsies from
different areas of the joint were combined in one block of tissue. Cryostat sections (5μm) were
cut, mounted on Star Frost adhesive glass slides (Knittelplaser, Baunschweig, Germany) and
stored at -80˚C.
All tissue staining, image acquisition and quantification took place in Birmingham and
was blinded to clinical outcomes. Prior to use, slides were thawed at room temperature (RT)
for 30 min. After fixation in acetone the sections were washed in PBS and blocked with 10%
normal human serum for 30 min at RT. Incubation with primary antibodies was performed
overnight at 4˚C in blocking solution. As primary antibodies, anti-CD55 (mouse IgG2a, clone
BU84; University of Birmingham, UK), anti-CD248 (mouse IgG1 supernatant, clone B1 35.1),
anti-FAP (mouse IgG1, clone F11-24; eBioscience), anti-podoplanin (mouse IgG1, clone
D2-40; AbD Serotec, Kidlington, UK), anti-CD31 (endothelial cell marker; mouse IgG2a,
clone HEC7; Thermo Scientific, Loughborough, UK), anti-CD68 (macrophage marker; mouse
IgG2b, clone Y1/82A; BD Pharmingen, Oxford, UK) were used. Tissue sections were incu-
bated for 1 hour at RT and bound primary antibodies were detected with goat antibodies
against mouse IgG1 conjugated with fluorescein (FITC), IgG2a conjugated with rhodamine
(TRITC) and IgG2b conjugated with cyanine 5 (Cy™ 5) (all Southern Biotech, Birmingham,
AL). To increase signal from FITC-channel, slides were stained for 30 min at RT with goat
anti-FITC Alexa-488 antibody (Invitrogen, Paisley, UK). All sections were co-stained with
Hoechst solution (Sigma-Aldrich Company Ltd., Gillingham, UK) to visualize cell nuclei.
As a negative control, a mixture of anti-IgG1, anti-IgG2a and anti-IgG2b secondary fluoro-
chrome-conjugated antibodies followed by anti-FITC Alexa-488 were applied to the sections
after omission of the primary antibodies. Images were acquired from 1–8 different regions of
each tissue section, using a Zeiss LSM 510 confocal scanning microscope and ZEN pro 2011
imaging software (Zeiss, Welwyn Garden City, UK). Settings within one staining experiment
remained unchanged. For each image, the number of pixels with intensity from 30 to 255 of
every fluorescent channel was quantified with ZEN pro 2011 and divided by a manually de-
fined area (μm2) only including tissue zones containing cells. The average number of fluores-
cent pixels with intensity 30–255 per unit area (pixel/UA) from all images within one synovial
tissue section was calculated. In addition, two researchers independently assessed the fluo-
rescence level of every marker using a semiquantitative scoring system of grade 0–4 combin-
ing staining intensity and number of positive cells. Semiquantitative scores correlated well
with unbiased pixel analysis scores (Spearman’s rho >0.7, p<0.001 for all markers; data not
shown). In order to assess differences in expression of the stromal markers FAP and podopla-
nin in different anatomical regions, lining and sublining regions were identified and pixel
counts individually quantified in 15 randomly selected samples from each of the early RA and
non-RA groups by a blinded observer.
During the study, tissues were stained for immunofluorescence on three separate occasions
in total, all performed in the Birmingham unit. In order to measure and account for any varia-
tion between staining of sections during different staining runs, we stained sections from the
same 11 patients on each occasion for a range of four stromal (CD55, CD248, FAP and podo-
planin) and two cellular (CD90, CD68) markers. Intraclass correlation coefficients (ICC) for
markers across runs were as follows reflecting good (ICC >0.7) internal consistency for all
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markers except CD248, which closely approached this level (ICC 0.69): CD55: ICC 0.77; FAP:
ICC 0.74; podoplanin: ICC 0.74; CD31: ICC 0.89; CD68: ICC 0.96.
For immunohistochemical staining, acetone fixed slides were re-hydrated in PBS for 10
minutes prior to blocking with Bloxall reagent (Vector Laboratories, California USA) for ten
minutes followed by 10% normal horse serum in PBS for a further 10 minutes. Slides were
stained using sheep anti FAP (R&D, AF3715) for 1 hour at RT. Slides were washed before
the application of donkey anti goat HRP (Dako). HRP staining was developed using the
ImmPACT DAB Peroxidase (HRP) Substrate (Vector Labs) and counterstained with haema-
toxylin. Slides were mounted in VectaMount (Vector Labs) before imaging using the Zeiss
Axio Scan and analysis using Zen lite 2012 software (both Zeiss, Oberkochen Germany).
Statistical analysis
Using Prism (Graphpad, La Jolla, CA) software, differences between groups were assessed
using the Kruskal-Wallis test with Dunn’s post test for multiple comparisons or the Mann-
Whitney test. The Chi-Square test was used to compare categorical characteristics. Correlation
of two outcome measurements was assessed with the Spearman rank-order correlation coeffi-
cient, using a Benjamini-Hochberg correction for multiple comparisons to exclude type I
errors. To assess reliability of outcome variables between multiple staining procedures, intra-
class correlation coefficients were calculated using SPSS (IBM, Armonk, NY). A p value <0.05
was considered statistically significant.
Results
Patient characteristics
Baseline characteristics of patients from the BEACON (Birmingham) and Synoviomics
(Amsterdam) cohorts presenting with symptom duration of three months or less are shown in
Table 1. In the very early rheumatoid arthritis (VERA) group, 78% already fulfilled the 2010
ACR/EULAR classification criteria for RA at baseline and 22% were first classified as having
UA. Eight patients in the VERA group had disease which was ultimately self-limiting. Most
patients in the non-RA group had a self-limiting disease, but eight had a persistent disease
with a diagnosis other than RA, including four with PsA. As expected, significantly more
patients were IgM-RF and/or ACPA positive in the VERA group compared to the non-RA
group, and tender and swollen joint counts were significantly higher in the VERA group.
FAP expression is increased in early arthritis patients who develop RA
In order to test the hypothesis that stromal markers would distinguish diagnostic group, we
compared the expression of CD55, CD248, podoplanin and FAP in different clinical outcome
groups (Fig 1). Baseline expression of FAP was significantly higher in patients fulfilling 2010
criteria for RA regardless of time of fulfilment of criteria compared to the comparison groups
(Kruskal-Wallis test p = 0.003, individual comparisons p<0.05 by Dunn’s post test). Signifi-
cantly higher expression of FAP in the VERA group was seen in the seronegative persistent RA
subgroup after excluding RA patients with self-limiting or seropositive disease (p = 0.0035
individual comparisons p<0.05, Fig 1A red data points), suggesting that FAP could be a useful
biomarker for seronegative persistent RA. Expression of podoplanin in VERA was increased
compared to non-inflammatory control samples (Kruskal-Wallis test p = 0.0062), but no speci-
ficity for RA vs other disease outcomes was seen. By comparison greater variability was seen in
CD55 and CD248 expression levels, and no difference was seen between different outcome
groups.
Stromal cell markers in early arthritis
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Stromal markers do not differentiate between persistent and resolving
disease
Having identified an association between FAP expression and the earliest clinically evident
stage of RA, we tested the hypothesis that stromal markers would differentiate between the key
prognostic outcomes of persistence or resolution in early arthritis. In our combined cohorts,
43% of patients presenting within the first three months of developing symptoms experienced
complete resolution of symptoms and signs that persisted in the absence of therapy during fol-
low-up. This proportion is consistent with that seen in previous work in the BEACON cohort
[3]. No significant differences were seen between resolving and persistent diseases for any of
the stromal markers analysed (Fig 2).
FAP expression is increased in both lining and sublining layers in VERA
patients
In early RA, strong FAP and gp38 staining was seen in the lining layer (Fig 3), but a network of
FAP positive cellular staining was also seen in the sublining layer that was not seen in non-RA
disease. Quantification of lining and sublining layer staining (Fig 3) demonstrated signifi-
cantly greater sublining FAP staining in early RA, confirming qualitative observations using
multicolour immunofluorescence staining (Fig 4 and Fig 5). Fluorescence staining for FAP
was validated using immunohistochemistry in sections from cohort patients; representative
images are shown in Fig 6.
Tissue FAP expression does not correlate with clinical or ultrasound
variables
Because FAP expression levels appeared to be associated with diagnostic outcome, we tested
whether FAP levels correlated with clinical variables including swollen and tender joint counts,






(n = 7) P-value
Age (years) 51 (43–59) 44 (35–60) 58 (46–69) 0.109
Female, n (%) 17 (53.1) 7 (29.2) 3 (42.9) 0.200
ESR (mm/h) 32.5 (15.3–61.8) 14 (7–39) - 0.068
CRP (mg/l) 12.3 (4.6–39.5) 9 (6–24) - 0.403
TJC68 8 (2–17) 2 (1–4) - 0.001
SJC66 7 (4–14) 2 (1–3) - <0.001
Symptom duration (wks) 6 (4–9) 4 (2–6) - 0.016
IgM-RF positive, n (%) 11 (34.4) 0 (0) - 0.001
ACPA positive, n (%) 14 (43.8) 0 (0) - < 0.001
IgM-RF and ACPA both positive, n (%) 10 (31.3) 0 (0) - 0.003
Self-limiting disease, n (%) 8 (25%) 16 (66.7) - 0.002
Diagnoses UA-RA 7 (SLD = 6)
RA-RA 25 (SLD = 2)
UA 10 (SLD = 7)
Gout 5 (SLD = 4)
PsA 4
Reactive 3 (SLD = 3)
Parvovirus 2 (SLD = 2)
Values shown are median (interquartile range) or number (percentage). ACPA: anti-citrullinated protein antibodies, CRP: C-reactive protein, ESR:
erythrocyte sedimentation rate, IgM-RF: IgM rheumatoid factor, PsA: psoriatic arthritis, RA-RA: patients who fulfil the 2010 ACR/EULAR classification
criteria for RA at baseline, SJC66: swollen joint count using 66 joints, SLD: self-limiting disease, TJC68: tender joint count using 68 joints, UA: unclassified
arthritis, UA-RA: patients who were classified as UA at baseline, but fulfilling the 2010 ACR/EULAR classification criteria for RA during follow-up, VERA:
very early rheumatoid arthritis.
https://doi.org/10.1371/journal.pone.0182751.t001
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erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and symptom duration. In the
entire cohort of patients with disease duration of three months or less (n = 56), FAP expression
levels demonstrated no correlation with these clinical variables after Benjamini-Hochberg
correction for multiple comparisons. Within the 23 individuals from Birmingham who had
undergone ultrasound scanning of the biopsied joint, there was no correlation between FAP
staining and either greyscale or power Doppler semiquantitative ultrasound grading scores.
Fig 1. Relationship between stromal markers and diagnostic group in treatment-naive early arthritis tissue. Expression of (A) FAP, (B)
podoplanin, (C) CD248, (D) CD55 were measured by pixel counting in synovial regions of interest in uninflamed tissue of patients with
mechanical joint symptoms undergoing exploratory arthroscopy (Control), and in baseline samples of early arthritis patients, split into patients
fulfilling ACR/EULAR 2010 criteria for RA during follow-up (very early rheumatoid arthritis; VERA) and combined non-RA groups made up of
patients with spontaneously resolving arthritis and patients with non-RA persistent arthritis (NON-RA). (A) FAP expression was higher in VERA
patients (n = 32) compared to other outcome groups (n = 24) (Kruskal-Wallis p = 0.0036, asterisks denote the results of Dunn’s post-test,
*p<0.05). Red data points indicate the subgroup of patients developing seronegative, persistent RA. (B) Podoplanin expression also differed
between outcome groups (Kruskal-Wallis p = 0.0062), but there was no significant difference in post-testing between VERA (n = 29) and
NON-RA groups (n = 23). (C,D) No significant difference was observed in CD55 (lining; 21 VERA vs 13 non-RA) or CD248 (sublining; 16 VERA
vs 8 non-RA) expression. Each dot represents a patient; median bars with interquartile ranges are shown.
https://doi.org/10.1371/journal.pone.0182751.g001
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Discussion
The most prominent stromal cell of the ST is the fibroblast-like synoviocyte (FLS) [7, 32]. We
previously showed that CD55 is a defining marker for FLS in the intimal lining layer where it
can mediate contacts with CD97 on other immune cells and may be of primary importance in
maintaining and amplifying synovial inflammation [13, 14, 33, 34]. Other molecules markedly
expressed by FLS in ST of patients with established RA are CD248 (also known as endosialin
or TEM1) and podoplanin (gp38) [16, 21]. CD248 is expressed by FLS in synovium from
patients with established PsA and RA, but is only weakly present in synovium from individuals
with non-inflammatory knee problems [16], and is believed to play a role in tissue remodelling
by increasing proliferation and migration [35]. FAP, a cell surface-bound, type II transmem-
brane glycoprotein belonging to the family of serine prolyl oligopeptidases, is expressed by
Fig 2. Relationship between stromal markers and prognostic outcome in treatment-naive early arthritis tissue.
Expression of (A) FAP (24 self-limiting vs 32 persistent disease), (B) podoplanin (20 self-limiting vs 32 persistent disease),
(C) CD248 (10 self-limiting vs 14 persistent disease), (D) CD55 (16 self-limiting vs 18 persistent disease) were measured by
pixel counting in synovial regions of interest in baseline samples of early arthritis patients who developed resolving disease
(self-limiting) or persistent disease. No significant differences were found. Each dot represents a patient; median bars with
interquartile ranges are shown. Significance of the comparisons was determined by the Kruskal-Wallis test.
https://doi.org/10.1371/journal.pone.0182751.g002
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activated fibroblasts associated with the granulation tissue of healing wounds and stroma of
epithelial cancers. It has also been shown that FAP is strongly expressed in rheumatoid syno-
vium [17]. Of these markers, podoplanin and FAP were found to be upregulated in early RA
ST compared to tissue of healthy controls, but only FAP expression appeared to differentiate
from other forms of inflammatory joint disease.
We found no correlation between FAP levels and clinical indices of disease activity. This
may in part be a consequence of exploratory analysis in a pilot study with moderate numbers.
However, it may not be reasonable to expect events in a single joint to reflect pathological
events at a systemic level. Existing data show that stromal cell activation profiles are specific to
organ and joint location[36, 37]; furthermore the role of stromal cell activation in such early
disease may relate to tissue remodelling to accommodate cellular infiltrates and the assembly
of pannus tissue capable of mediating joint damage [10, 22]. These pathological processes may
not necessarily be reflected in markers of systemic inflammation, as evidenced by longstanding
observations of progression of erosion despite apparent clinical remission [38]. Imaging stud-
ies have shown that persistent joint inflammation may account for progression of joint damage
[39, 40]. We therefore investigated the link between synovial hypertrophy, Power Doppler
enhancement and stromal marker expression. There was no correlation between local ultra-
sound indices and stromal markers, however we have to regard these data with caution given
the limited number of patients with such data available. Larger ongoing studies are addressing
this hypothesis.
FAP is strongly expressed in ST of patients with destructive RA [17]. It is a surface glyco-
protein with both ectoenzyme and transmembrane signalling properties. Ospelt et al. blocked
the serine protease ectoenzyme function of FAP in fibroblasts and in the SCID model of fibro-
blast co-implantation, resulting in increased matrix metalloproteinase production and carti-
lage breakdown [19], suggesting a protective role of FAP. However subsequent studies have
uncovered multiple additional roles of FAP. Wa¨ldele et al. knocked out FAP in the human
Fig 3. Differences in lining and sublining layer staining patterns of stromal markers with disease. Expression of (A) FAP and (B)
podoplanin quantified in lining and sublining layer regions in 15 sections from each group. FAP: Kruskal-Wallis p<0.0001, podoplanin
p<0.0001; asterisks denote the results of Dunn’s post-test, **p<0.01).
https://doi.org/10.1371/journal.pone.0182751.g003
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Fig 4. FAP is expressed at high levels throughout the synovium in biopsies of patients developing RA. (A) Multicolour
confocal microscopy images are shown for tissue staining at baseline with FAP (F11-24), podoplanin (D2-40), CD68 (Y1-82A),
Stromal cell markers in early arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0182751 August 9, 2017 10 / 17
tumour necrosis factor (TNF) transgenic model of arthritis, resulting in decreased matrix
destruction with no effect on synovial hyperplasia or bone erosion; decreased adhesion to car-
tilage suggested that surface interactions with β1 integrins on the cell surface was a likely
mechanism [41]. Various transmembrane signalling pathways have been implicated in the
non-proteolytic activity of FAP; in bone marrow stromal cells FAP regulates cellular migration
via modulation of RhoA, whilst in epithelial cells regulation of PI3Kinase and Ras/ERK signal-
ling have been demonstrated [42, 43]. In our study cohort, we showed a strong expression of
FAP in ST of RA patients early in their disease course. High expression of this marker in both
lining and sublining regions of the ST indicates the involvement of dysregulated extracellular
matrix remodelling in the early stage of arthritis that could represent a potential therapeutic
target in early disease. Nuclear medicine imaging of FAP is already under development, facili-
tated by the development of monoclonal antibodies in oncology [44]. Furthermore, the recent
observation that FAP positive cancer associated fibroblasts are present in the peripheral blood
of metastatic breast cancer patients may throw interesting light upon the ability of synovial
fibroblasts to spread to distant sites in mouse models of arthritis [45, 46]. Placing our findings
in this context, FAP and other stromal markers may have significant roles to play as potential
therapeutic targets.
RA FLS show a gene expression profile reminiscent of myofibroblasts, and cells of the inti-
mal lining layer in RA have been found to express α-smooth muscle actin (α-SMA) and type
IV collagen [47, 48]. It has therefore been suggested that RA FLS can undergo a process resem-
bling epithelial-mesenchymal transition (EMT), whereby static epithelial cells lose cell-cell
contacts, acquire mesenchymal features and manifest a migratory phenotype. This phenome-
non is common to early developmental processes, tissue repair, fibrosis and carcinogenesis.
Both podoplanin and FAP are known to be involved in EMT and are reported to be highly
expressed in cells of the intimal lining layer in RA, with little expression in osteoarthritis syno-
vium [21, 49]. The role of podoplanin in inflamed synovial tissue is unclear, but it is possible
that it could relate to interactions with infiltrating leukocyte sub-populations, as seen in podo-
planin expressing fibroblast-like reticular cells and lymphatic endothelium of the lymph node
[20]. Ultimately this could favour the formation of ectopic lymphoid structures [50]. Since we
found upregulation of podoplanin in ST of patients with early RA, the involvement of this
marker in an EMT-like differentiation of RA-FLS into myofibroblasts could be of importance
in the earlier stages of arthritis.
One of the challenges in the treatment of early arthritis patients is initiating patient tailored
treatment as early as possible [51–53]. Personalized medicine in this patient group is aimed at
remission, thereby preventing joint destruction and optimizing functional outcome with a
minimum of potential harmful side-effects. Despite the importance of making an early diagno-
sis, in over 40% of rheumatology patients no diagnosis can be made at presentation [3], indi-
cating a need for new diagnostic and prognostic markers. Our findings suggest that synovial
stromal marker analysis could play a role alongside other tissue markers in the guidance of
treatment decisions in early arthritis patients where outcome is not possible to predict using
existing clinical variables [6]. Given these preliminary results, both validation in larger cohorts
and combination with other variables are necessary in order to provide clear guidance for cli-
nicians. Our findings and those of others mandate more extensive studies of candidate tissue
markers alone and in combination for the prediction of diagnosis and prognosis in larger
CD90 (Thy-1A1) antibodies followed by secondary agents, and nuclear (Hoechst) stain in a representative patient presenting with
RA whose disease persisted. (B) Higher magnification, merged image. The region representing the lining layer is highlighted by a
dotted line.
https://doi.org/10.1371/journal.pone.0182751.g004
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Fig 5. FAP is expressed at low levels in synovial biopsies of patients with self-limiting disease. (A) Multicolour confocal
microscopy images are shown for tissue staining at baseline with FAP (F11-24), podoplanin (D2-40), CD68 (Y1-82A), CD90 (Thy-1A1)
antibodies followed by secondary agents, and nuclear (Hoechst) stain in a patient with unclassified arthritis whose disease
spontaneously resolved. (B) Higher magnification, merged image. The region representing the lining layer is highlighted by a dotted line.
https://doi.org/10.1371/journal.pone.0182751.g005
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Fig 6. High expression of FAP in tissue from patient developing RA compared to UA control. Immunohistochemistry
was used to stain for FAP positive cells using a sheep anti-FAP antibody in representative tissues from patients developing
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cohorts of patients with early disease [54]. It would also be useful to examine novel tissue
markers in the synovium of individuals at risk of developing RA in order to build upon exist-
ing studies using conventional histology, leukocyte and adhesion markers [55].
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